NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.
Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.
